Skip to main content
. Author manuscript; available in PMC: 2007 Sep 20.
Published in final edited form as: Exp Hematol. 2005 Dec;33(12):1427–1435. doi: 10.1016/j.exphem.2005.06.032

Table 5.

Haploidentical transplant for patients with hematologic malignancy: Roger Williams data

Diagnosis Age (y) CD3+ cells/kg CD34+ cells/kg Maximal chimerism Response Survival (d)
MDS-AML 65 1 × l06 4.0 × 106 0% Transient response 66
MDS-AML 72 1 × l08 7.4 × 106 0% Died in CR of unrelated cause 180
AML 52 1 × l08 7.7 × 106 N/A NA 6
MDS-AML 63 2 × 108 3.2 × 106 0% 2 wk CR × 8.4 mo 372
AML 58 2 × 108 7.6 × 106 0% 2 wk CR × 31 mo. Back in CR day + 72 2nd BMT 1167a,b
AML 71 2 × 108 8.1 × 106 0% 2 wk Transient response 22
AML 72 2 × 108 4.3 × 106 17% 2 wk temporary Transient response 145
AML 80 2 × l08 7.8 × 106 48% 2 wk Transient response 25
AML 44 2 × 108 2.9 × 106 0% 2 wk Remains in CR 732a,b
AML 70 2 × 108 10.3 × 106 0% 2 wk Transient response 100
AML 72 2 × 108 2.4 × 106 63% day + 1
0% 1 wk		 Transient response 95
AML 82 2 × 108 2.9 × 106 11% day + 1
0% 1 wk		 Transient response 67
AML 59 2 × l08 13.5 × 106 0% 2 wk Transient response 97
Lymphoma 49 3 × 107 2.9 × 106 0% 2 wk Partial response
In CR after auto BMT		 1369a,b
Lymphoma 54 1 × l08 4.0 × 106 0% 2 wk Progression treated in 2nd CR 442
Lymphoma 58 2 × l08 2.8 × 106 100% Died of acute GVHD 30
Lymphoma 50 1 × l08 1.0 × 106 0% 2 wk Attained CR, minimal relapse marrow only 1249a
a

Patient currently alive;

b

Disease-free.